文献速递糖尿病

全基因组关联分析鉴定与SUGAR-MGH中二甲双胍和格列吡嗪急性反应相关的祖先特异性遗传变异

Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
PubMed 文献 · Diabetologia · 2023-05-26

AIMS/HYPOTHESIS: Characterisation of genetic variation that influences the response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes.…

要点

  • 非洲祖先特异性变异rs149403252与二甲双胍后空腹血糖降幅增大0.94 mmol/l相关(p=1.9×10-9)。
  • rs111770298携带者二甲双胍后空腹血糖升高0.29 mmol/l,非携带者降低0.15 mmol/l(p=2.4×10-8)。
  • 糖尿病预防计划中rs111770298杂合携带者治疗1年后HbA1c升高0.08%,非携带者升高0.01%(p=3.3×10-3)。

核心结论

  • 研究提供了表型明确、基因分型密集的多祖先资源,用于研究基因-药物相互作用,发现与常用降糖药反应相关的新变异,并为2型糖尿病相关变异的机制提供线索。

研究设计与样本

  • 使用Illumina多民族基因分型芯片进行全基因组关联分析,并用TOPMed参考面板进行填充。
  • 采用加性模型的多元线性回归检验遗传变异与药物反应主要终点的关联。
  • 重点分析评估了804个独特的2型糖尿病和血糖性状相关变异对SUGAR-MGH结局的影响,并进行共定位分析。

主要发现

  • 共发现5个与二甲双胍或格列吡嗪反应相关的全基因组显著变异。
  • 非洲祖先特异性变异rs149403252(MAFAfr=0.0283)与二甲双胍后第2次访视空腹血糖较低相关(p=1.9×10-9),携带者空腹血糖降幅增大0.94 mmol/l。
  • 非洲祖先特异性变异rs111770298(MAFAfr=0.0536)与二甲双胍反应减弱相关(p=2.4×10-8),携带者空腹血糖升高0.29 mmol/l,非携带者降低0.15 mmol/l。
  • 糖尿病预防计划中验证rs111770298与二甲双胍血糖反应较差相关:杂合携带者治疗1年后HbA1c升高0.08%,非携带者升高0.01%(p=3.3×10-3)。
  • 发现2型糖尿病相关变异与血糖反应的关联,包括ZMIZ1附近rs703972的2型糖尿病保护性C等位基因与活性GLP-1水平升高相关(p=1.6×10-5)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Characterisation of genetic variation that influences the response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) examined the acute response to metformin and glipizide in order to identify new pharmacogenetic associations for the response to common glucose-lowering medications in individuals at risk of type 2 diabetes. METHODS: One thousand participants at risk for type 2 diabetes from diverse ancestries underwent sequential glipizide and metformin challenges. A genome-wide association study was performed using the Illumina Multi-Ethnic Genotyping Array. Imputation was performed with the TOPMed reference panel. Multiple linear regression using an additive model tested for association between genetic variants and primary endpoints of drug response. In a more focused analysis, we evaluated the influence of 804 unique type 2 diabetes- and glycaemic trait-associated variants on SUGAR-MGH outcomes and performed colocalisation analyses to identify shared genetic signals. RESULTS: Five genome-wide significant variants were associated with metformin or glipizide response. The strongest association was between an African ancestry-specific variant (minor allele frequency [MAFAfr]=0.0283) at rs149403252 and lower fasting glucose at Visit 2 following metformin (p=1.9×10-9); carriers were found to have a 0.94 mmol/l larger decrease in fasting glucose. rs111770298, another African ancestry-specific variant (MAFAfr=0.0536), was associated with a reduced response to metformin (p=2.4×10-8), where carriers had a 0.29 mmol/l increase in fasting glucose compared with non-carriers, who experienced a 0.15 mmol/l decrease. This finding was validated in the Diabetes Prevention Program, where rs111770298 was associated with a worse glycaemic response to metformin: heterozygous carriers had an increase in HbA1c of 0.08% and non-carriers had an HbA1c increase of 0.01% after 1 year of treatment (p=3.3×10-3). We also identified associations between type 2 diabetes-associated variants and glycaemic response, including the type 2 diabetes-protective C allele of rs703972 near ZMIZ1 and increased levels of active glucagon-like peptide 1 (GLP-1) (p=1.6×10-5), supporting the role of alterations in incretin levels in type 2 diabetes pathophysiology. CONCLUSIONS/INTERPRETATION: We present a well-phenotyped, densely genotyped, multi-ancestry resource to study gene-drug interactions, uncover novel variation associated with response to common glucose-lowering medications and provide insight into mechanisms of action of type 2 diabetes-related variation. DATA AVAILABILITY: The complete summary statistics from this study are available at the Common Metabolic Diseases Knowledge Portal ( https://hugeamp.org ) and the GWAS Catalog ( www.ebi.ac.uk/gwas/ , accession IDs: GCST90269867 to GCST90269899).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Li JH, Brenner LN, Kaur V, et al. Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH. Diabetologia. 2023. PMID: 37233759. doi:10.1007/s00125-023-05922-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。